The drug abiraterone acetate gave men with advanced prostate cancer an average of four months of extra life, according to Phase III trial results published in the New England Journal of Medicine today.
Abiraterone acetate, trade name Zytiga™, was discovered at The Institute of Cancer Research (ICR) in what is now the Cancer Research UK Cancer Therapeutics Unit. It was first trialled at The Royal Marsden Hospital.
Cancer Research Technology assigned abiraterone acetate to BTG International Ltd, who in turn licensed it to Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology Inc., now a member of the Janssen Pharmaceutical Companies. Visit our Track Record page for more information about the CRT clinical pipeline.